Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drug developer Vertex Pharmaceuticals
With that in mind, let's take a closer look at Vertex's business and see what CAPS investors are saying about the stock right now.
|Headquarters (founded)||Cambridge, Mass. (1989)|
|Market Cap||$8.5 billion|
|Trailing-12-Month Revenue||$1.4 billion|
|Management||Dr. Jeffrey Leiden (since February 2012)
CFO Ian Smith (since October 2001)
|Return on Equity (average, past 3 years)||(61.6%)|
|Cash/Debt||$968.9 million / $400.0 million|
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 92% of the 716 members who have rated Vertex believe the stock will outperform the S&P 500 going forward.
Just gettin started -- looked at [price-to-sales] compared with [Alexion Pharmaceuticals] and this one has so much upside it astounds me. 2nd blockbuster Kalydeco coming along and then possible expansion to other [cystic-fibrosis] patients, combined with fact of all oral HCV treatments being tested and INCIVEK blockbuster profit machine for next couple years ... count me in.
If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite a strong four-star rating, Vertex may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now
Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Vertex. Try any of our Foolish newsletter services free for 30 days.